Role of hydrogen sulfide in systemic and pulmonary hypertension: Cellular mechanisms and therapeutic implications

Joshua Brampton; Philip I. Aaronson

Role of hydrogen sulfide in systemic and pulmonary hypertension: Cellular mechanisms and therapeutic implications

Joshua Brampton, Philip I. Aaronson^*

^*Corresponding author for this work

King's College London

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

There is increasing interest in the possible therapeutic benefits of the gasotransmitter hydrogen sulfide (H₂S; sulfide), and drugs which release sulfide are currently being evaluated in both preclinical and clinical studies as treatments for conditions ranging from cancer to cardiovascular disease to inflammation. Sulfide is generally considered to act as a vasodilator, and it is therefore not surprising that the effects of sulfide donors on both systemic and pulmonary hypertension are being examined. In this review, we provide a critical evaluation of both the evidence that H₂S may be of benefit in treating systemic and pulmonary hypertension, and of current hypotheses regarding the cellular mechanisms underlying sulfide’s effects on the systemic and pulmonary vascular systems.

Original language	English
Pages (from-to)	4-22
Number of pages	19
Journal	Cardiovascular & hematological agents in medicinal chemistry
Volume	14
Issue number	1
Publication status	Published - 1 Apr 2016

Keywords

Cystathionine γ lyase
Endothelium derived hyperpolarization
Hydrogen sulfide
Hypertension
Nitric oxide
Pulmonary hypertension
Sulfhydration

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0832d8ac0fc9404d89be9c03733102b1,

title = "Role of hydrogen sulfide in systemic and pulmonary hypertension: Cellular mechanisms and therapeutic implications",

abstract = "There is increasing interest in the possible therapeutic benefits of the gasotransmitter hydrogen sulfide (H2S; sulfide), and drugs which release sulfide are currently being evaluated in both preclinical and clinical studies as treatments for conditions ranging from cancer to cardiovascular disease to inflammation. Sulfide is generally considered to act as a vasodilator, and it is therefore not surprising that the effects of sulfide donors on both systemic and pulmonary hypertension are being examined. In this review, we provide a critical evaluation of both the evidence that H2S may be of benefit in treating systemic and pulmonary hypertension, and of current hypotheses regarding the cellular mechanisms underlying sulfide{\textquoteright}s effects on the systemic and pulmonary vascular systems.",

keywords = "Cystathionine γ lyase, Endothelium derived hyperpolarization, Hydrogen sulfide, Hypertension, Nitric oxide, Pulmonary hypertension, Sulfhydration",

author = "Joshua Brampton and Aaronson, {Philip I.}",

year = "2016",

month = apr,

day = "1",

language = "English",

volume = "14",

pages = "4--22",

journal = "Cardiovascular & hematological agents in medicinal chemistry",

issn = "1871-5257",

publisher = "Bentham Science Publishers B.V.",

number = "1",

}

TY - JOUR

T1 - Role of hydrogen sulfide in systemic and pulmonary hypertension

T2 - Cellular mechanisms and therapeutic implications

AU - Brampton, Joshua

AU - Aaronson, Philip I.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - There is increasing interest in the possible therapeutic benefits of the gasotransmitter hydrogen sulfide (H2S; sulfide), and drugs which release sulfide are currently being evaluated in both preclinical and clinical studies as treatments for conditions ranging from cancer to cardiovascular disease to inflammation. Sulfide is generally considered to act as a vasodilator, and it is therefore not surprising that the effects of sulfide donors on both systemic and pulmonary hypertension are being examined. In this review, we provide a critical evaluation of both the evidence that H2S may be of benefit in treating systemic and pulmonary hypertension, and of current hypotheses regarding the cellular mechanisms underlying sulfide’s effects on the systemic and pulmonary vascular systems.

AB - There is increasing interest in the possible therapeutic benefits of the gasotransmitter hydrogen sulfide (H2S; sulfide), and drugs which release sulfide are currently being evaluated in both preclinical and clinical studies as treatments for conditions ranging from cancer to cardiovascular disease to inflammation. Sulfide is generally considered to act as a vasodilator, and it is therefore not surprising that the effects of sulfide donors on both systemic and pulmonary hypertension are being examined. In this review, we provide a critical evaluation of both the evidence that H2S may be of benefit in treating systemic and pulmonary hypertension, and of current hypotheses regarding the cellular mechanisms underlying sulfide’s effects on the systemic and pulmonary vascular systems.

KW - Cystathionine γ lyase

KW - Endothelium derived hyperpolarization

KW - Hydrogen sulfide

KW - Hypertension

KW - Nitric oxide

KW - Pulmonary hypertension

KW - Sulfhydration

UR - http://www.scopus.com/inward/record.url?scp=84978180060&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84978180060

SN - 1871-5257

VL - 14

SP - 4

EP - 22

JO - Cardiovascular & hematological agents in medicinal chemistry

JF - Cardiovascular & hematological agents in medicinal chemistry

IS - 1

ER -

Role of hydrogen sulfide in systemic and pulmonary hypertension: Cellular mechanisms and therapeutic implications

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this